What is the optimal management of hypertension in an elderly female in her late 80s with end‑stage renal disease on dialysis, residing in a nursing home, whose systolic blood pressure fluctuates between 130 and 182 mm Hg while she is taking amlodipine 2.5 mg daily?

Optimal Management of Hypertension in an Elderly Dialysis Patient

Continue amlodipine 2.5 mg daily and prioritize aggressive volume management through dialysis optimization and sodium restriction before escalating antihypertensive therapy, as volume overload is the primary driver of hypertension in dialysis patients. 1

Blood Pressure Targets in This Population

The blood pressure targets for this patient require careful consideration of multiple factors:

• For frail elderly or nursing home residents with high comorbidity burden (which applies to this late-80s ESRD patient), target systolic blood pressure is 140-150 mmHg, not the intensive <130/80 mmHg target used for robust community-dwelling elderly 2
• Her current systolic BP range of 130-182 mmHg indicates she is sometimes at goal (when at 130-140s) but frequently elevated (when approaching 182 mmHg) 2
• The 2017 ACC/AHA guidelines emphasize individualization based on frailty status rather than age alone, and nursing home residence with ESRD on dialysis clearly indicates high frailty 2

Volume Management as First-Line Therapy

Before any medication adjustment, volume status must be optimized:

• Address volume overload through dialysis optimization (adequate ultrafiltration) and sodium restriction, as volume excess underlies most hypertension in dialysis patients 1
• Target predialysis BP should be 140/90 mmHg through volume management alone before escalating pharmacotherapy 1
• Never initiate or escalate antihypertensives without first assessing volume status, as most dialysis hypertension is volume-mediated 1

Current Medication Assessment

Amlodipine 2.5 mg daily is an appropriate choice for this patient:

• Amlodipine reduced cardiovascular events versus placebo in hypertensive hemodialysis patients in randomized controlled trials 1
• Amlodipine is associated with decreased total and cardiovascular mortality in observational studies of dialysis patients 1
• Amlodipine has demonstrated cardiovascular benefit in hemodialysis patients with hypertension, with RCT evidence showing reduced cardiovascular events compared to placebo 3
• The 2.5 mg dose is appropriately conservative given her advanced age, as elderly patients have decreased clearance of amlodipine with a resulting increase of AUC of approximately 40 to 60% 4

Medication Escalation Algorithm (If Volume Optimization Fails)

If blood pressure remains elevated after achieving euvolemia:

• First option: Increase amlodipine to 5 mg daily (still within safe range for elderly, as amlodipine 2.5-5 mg is effective in elderly patients) 4
• Second option: Add a beta-blocker if coronary artery disease or heart failure is present (preferably nondialyzable like carvedilol or propranolol if no intradialytic hypotension) 1
• Third option: Add an ACE inhibitor or ARB as second agent, particularly if residual kidney function exists (may preserve residual renal function and reduce left ventricular mass) 1

Critical Pitfalls to Avoid

• Do not add thiazide diuretics (HCTZ)—they have minimal effect on central hemodynamic indices in dialysis patients and should not be considered antihypertensive medications in this setting 3
• HCTZ requires functioning nephrons to work, and in anuric or near-anuric dialysis patients, thiazides cannot exert their diuretic effect 3
• Avoid non-dihydropyridine calcium channel blockers (diltiazem, verapamil) if heart failure is present 3
• Check for postural hypotension regularly when treating with any BP-lowering drugs, as orthostatic hypotension risk increases with frailty 1
• Monitor for amlodipine side effects including edema, palpitations, dizziness, and flushing, which are more common at higher doses 5

Monitoring Strategy

• Measure standing blood pressure at each visit to assess for orthostatic hypotension 2
• If available, use home or ambulatory BP monitoring, as elevated BP by home or ambulatory BP monitoring is clearly associated with shorter survival in dialysis patients 6
• Predialysis and postdialysis BP measurements display a J-shaped or U-shaped association with outcomes due to low accuracy and peculiar hemodynamic settings related to dialysis 6
• Monitor for hyperkalemia if ACE inhibitors/ARBs are added 3